RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
0.9413
-0.0087 (-0.92%)
At close: Dec 5, 2025, 4:00 PM EST
0.9900
+0.0487 (5.17%)
After-hours: Dec 5, 2025, 6:40 PM EST
RenovoRx Employees
RenovoRx had 10 employees as of December 31, 2024. The number of employees increased by 2 or 25.00% compared to the previous year.
Employees
10
Change (1Y)
2
Growth (1Y)
25.00%
Revenue / Employee
$92,800
Profits / Employee
-$1,110,500
Market Cap
34.50M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10 | 2 | 25.00% |
| Dec 31, 2023 | 8 | -1 | -11.11% |
| Dec 31, 2022 | 9 | 3 | 50.00% |
| Dec 31, 2021 | 6 | -3 | -33.33% |
| Dec 31, 2020 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RNXT News
- 5 days ago - RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th - GlobeNewsWire
- 17 days ago - RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th - GlobeNewsWire
- 23 days ago - RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update - GlobeNewsWire
- 4 weeks ago - RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD - GlobeNewsWire
- 4 weeks ago - RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th - GlobeNewsWire
- 5 weeks ago - RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET - GlobeNewsWire
- 2 months ago - RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD - GlobeNewsWire
- 2 months ago - RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites - GlobeNewsWire